Dr. Di Paola got her doctorate in Chemical Industrial Processes at the University Roma “La Sapienza”. She collaborated, during her doctorate, with prof. JM Prausnitz and H. Blanch at the University of California at Berkeley. Currently she is Assistant Professor at the University Campus Biomedico in Rome. Her research interests span from bioinformatics to biotechnological processes. She’s author of 45 papers on international journals and books. She’s Editor-in-chief of the "International Journal of Biochemistry Research & Review", Associate Editor for Journal of Physical Chemistry & Biophysics; Advances in Systems Biology; International Journal of Medical Biotechnology & Genetics(IJMBG) and Book Review Editor for "Current Bioinformatics". She was in the Organizing Committee of 5th Global Chemistry Congress (London, September 04-06 2017) and she will be part of the Organizing Committee of the forthcoming Euro Chemistry Conference (Rome, June 11-13, 2018) and of the 7th World Congress Nanotechnology & Materials Science (Frankfurt, November 05-07, 2018).
Iron overload is one of mechanisms by which HCV causes oxidative stress that may contribute to liver fibrosis and carcinogenesis. The therapeutic benefit of adding iron chelators to treatment regimen of HCV patients are warranted because: firstly, clinical data reported that excess iron deposits are found in the liver samples from about 20% of HCV-positive patients. Secondly, hepatic iron load enhances the levels of eukaryotic initiation factor 3, which is essential for HCV translation. Through an international joint project entitled "Investigating the coagulation profiles and the role of iron in patients with hepatitis C virus (HCV): Impact of iron chelators in attenuating thrombosis and liver fibrosis", we investigated the potential antifibrotic effects of different iron chelators, and the underlying mechanisms through studying different oxidative stress, inflammatory and fibrotic markers.
Dr Sergey Suchkov, MD, PhD. Professor in Immunology & Medicine. Personal: Born 11 January 1957, Astrakhan, Russia. divorced; two sons. Education: MD, Astrakhan State Medical University, Russia, 1980; PhD, I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology, USSR Academy of Medical Sciences, 1985; Doctor Degree, National Institute of Immunology, Russia, 2001. Positions held: Post Doc Research Associate, Institute of Medical Enzymology, 1985-87; Senior Research Associate, Koltzov Institute of Developmental Biology, USSR Academy of Sciences, 1987-89; Head of the Lab of Immunology and Immunobiotechnology, Helmholtz Eye Research Institute in Moscow, 1989-95; Trainee, Laboratory of Immunology, NEI, Bethesda, MD, USA, NIH and Laboratory of Immunology, Wills Eye Hospital, Philadelphia, USA, as well as at some of the British Universities on the invitation of the Royal Society for Immunology, 1989; Chairman, Department for Clinical Immunology, Moscow Clinical Research Institute and the Immunologist-in-Chief of the Moscow Regional Ministry of Health, 1995-2004; Executive Secretary-in-Chief of the Editorial Board, Biomedical Science International journal, 1993-1996; Professor in Medicine and Immunology, I.M. Sechenov First Moscow Medical University and Faculty Chairman & Director of the Department of Preventive, Personalized and Translational Medicine, A.I.Evdokimov Moscow State University of Medicine & Dentistry. Honours: Secretary General, United Cultural Convention, Cambridge, UK. Memberships: New York Academy of Sciences, USA; European Association for Predictive, Preventive and Personalized Medicine, Brussels; American Association for Research in Vision and Ophthalmology; International Society for Eye Research; EPMA Journal, Personalized Medicine Universe, Open J.Autoimmunity and American J.Cardiovascular Res. Editorial Boards; All-Union (from 1992 - Russian) Biochemical Society; All-Union (from 1992 - Russian) Immunological Society.
Suneela Dhaneshwar Ph.D. is the Director of Amity Institute of Pharmacy, Deputy Dean of Research and Head; Directorate of Research & Publications at Amity University Uttar Pradesh, Lucknow Campus, Lucknow, UP, India. She is a Professor of Pharmaceutical Chemistry with 23 years of teaching and 28 years of research experience. She earned her Ph. D. in Pharmaceutical Sciences from Devi Ahilya Vishwavidyalaya Indore, India in 1996 with a special emphasis on designing prodrug strategies to lower ulcerogenic potential of nonsteroidal anti-inflammatory drugs for which she was awarded Senior Research Fellowship from Council for Scientific and Industrial Research, New Delhi, India.
Prof. Imran Ali is a world recognized highly cited academician and researcher. He completed his Ph.D. at the age of 28 years from Indian Institute of Technology Roorkee, Roorkee, India. Prof. Ali is known globally due his great contribution in anti-cancer and chiral drugs development and water treatment. He has published more than 400 papers in reputed journals including papers in Nature and Chemical Reviews of more than 46 impact factors. He has also five books published by Marcel Dekker, Inc., USA; Taylor & Francis, USA; John Wiley & Sons, USA; John Wiley & Sons, UK; Elsevier, The Netherlands. His citation is 14,500 with h-index 49 and i10-index 180.
Nature and Chemical Reviews ,Anticancer Drugs
Mr. Bianchi is currently the President and Chief of Scientific and Technical Affairs at the Prescription Drug Research Center, Bradenton, FL. He retired as a laboratory director for the Drug Enforcement Administration after 34 years of federal service, where he held increasingly responsible positions as an analytical chemist for the FDA and DEA to the chief of DEA's Laboratory Operations Section. Mr. Bianchi was also director of the DEA Special Testing and Research Laboratory where extractability experiments were conducted more than twenty years ago. Since 2005 he has been working with the pharmaceutical industry and FDA on developing in vitro protocols to evaluate abuse deterrent formulations and has been actively involved is sharing his experience with the regulatory, treatment, pharmaceutical abuse and law enforcement community. For the last decade, he has participated dozens of category 1 studies on abuse-deterrent opioid formulations, appeared as a panelist and presenter at abuse deterrent formulation & prescription drug abuse professional meetings. Mr. Bianchi has provided drug related consultations to more than thirty organizations/companies concerned about OTC & prescription drug abuse and has made numerous presentations to the regulatory, treatment, pharmaceutical, abuse and law enforcement communities. Mr. Bianchi is also a Special Government Employee for participation in the FDA Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee meetings.
Drug Safety and Risk Management
CEO and Founder of Biotechnology and Regenerative Medicine at RegenerAge International ™ . Vice President of International Clinical Development for Bioquark, Inc. and Chief Clinical Officer at ReAnima™ Advanced Biosciences . Advance Fellow by the American Board of Anti-Aging and Regenerative Medicine , Visiting Scholar at University of North Carolina at Chapel Hill . Fellow in Stem Cell Medicine by the American Academy of Anti-Aging Medicine and University of South Florida.